Effects of Cannabidiol on the In Vitro Lymphocyte Pro-Inflammatory Cytokine Production of Senior Horses.
Authors: Turner Shelley, Barker Virginia Day, Adams Amanda A
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Cannabidiol as an Anti-Inflammatory Agent in Senior Horses Chronic inflammatory conditions represent a significant clinical challenge in geriatric equine populations, prompting investigation into novel therapeutic compounds. Researchers isolated peripheral blood mononuclear cells (PBMCs) from senior horses and exposed them to increasing concentrations of purified CBD (99.9%) to evaluate dose-dependent effects on pro-inflammatory cytokine production; cells were stimulated with PMA/ionomycin and analysed via flow cytometry and RT-PCR for interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and cannabinoid receptor expression. At 4 µg/mL—the highest concentration that did not compromise cell viability—CBD significantly suppressed production of both IFN-γ and TNF-α, with gene expression analysis confirming reduced mRNA levels for these inflammatory mediators and downregulation of IL-10; cannabinoid receptor expression (CB1 and CB2) showed dose-dependent increases at higher concentrations (10 µg/mL), suggesting CBD acts through specific receptor pathways. Whilst these in vitro findings are encouraging and warrant progression to in vivo studies, practitioners should recognise this represents foundational cellular work rather than clinical evidence; the practical implications remain speculative until efficacy, bioavailability, and appropriate dosing protocols are established in living horses with documented inflammatory conditions.
Read the full abstract on PubMed
Practical Takeaways
- •This in vitro evidence suggests CBD may have anti-inflammatory potential for senior horses with chronic inflammatory conditions, warranting further clinical investigation
- •CBD demonstrated cytotoxic effects at higher concentrations (above 4 µg/mL), highlighting the importance of dose optimization in any future therapeutic applications
- •Results are preliminary in vitro findings and cannot yet be translated to clinical dosing or efficacy in living horses without further in vivo studies
Key Findings
- •CBD at 4 µg/mL did not affect PBMC viability and was identified as the optimal non-cytotoxic concentration
- •CBD at 4 µg/mL significantly reduced production of IFN-γ and TNF-α pro-inflammatory cytokines (P < 0.05)
- •RT-PCR gene expression showed CBD reduced TNF-α and IFN-γ mRNA at 4 µg/mL and IL-10 at both 2 and 4 µg/mL
- •CBD at 10 µg/mL significantly upregulated CB1 and CB2 receptor gene expression